 The goal of this study is to preliminarily determineestimate feasibility and whether frequent and early conivaptan use, at a dose currently determined to be safe i.e., 40mgday, is safe and well-tolerated in patients with cerebral edema from intracerebral hemorrhage ICH and pressure ICP. A further goal is to preliminarily estimate whether conivaptan at this same dose can reduce cerebral edema CE in these same patients. This study is also an essential first step in understanding the role of conivaptan in CE management. 